Forecast 1-Year Return: Stocks with a red number are projected to decline by that percentage over the next 12 months. Stocks with a black number are projected to move higher by that percentage over the next 12 months.
Value Level: The price at which to enter a GTC Limit Order to buy on weakness. The letters mean; W-Weekly, M-Monthly, Q-Quarterly, S-Semiannual and A- Annual.
Pivot: A level between a value level and risky level that should be a magnet during the timeframe noted.
Risky Level: The price at which to enter a GTC Limit Order to sell on strength.
Abbott Labs (ABT) ($64.52 vs $66.03 on Aug 8) still has a buy rating according to ValuEngine with the stock above its 200-day simple moving average at $62.89. My annual value level is $59.79 with a quarterly pivot at $63.28 and weekly risky level at $68.62. Amgen (AMGN) ($85.34 vs $81.57 on Aug 8) still has a buy rating and is above its 200-day SMA at $75.08. My quarterly value level lags at $77.19 with a weekly pivot at $86.33 and monthly risky level at $88.72. Bristol-Myers (BMY) ($32.62 vs $32.54 on Aug 8) still has a buy rating with the stock below its 200-day SMA at $33.42. My annual value level is $30.23 with a weekly pivot at $33.62 and monthly risky level at $35.67. Express Scripts (ESRX) ($54.95 vs $56.02 on Aug 8) still has a buy rating with the stock below its 200-day SMA at $56.77. My semiannual value level is $44.43 with a semiannual pivot at $53.18 and quarterly risky level at $58.12. Gilead Sciences (GILD) ($65.45 vs $57.55 on Aug 8) has been downgraded to hold from buy since Aug. 8 with the stock above its 200-day SMA at $54.34. My quarterly value level is $60.53 with a monthly risky level at $68.87. Johnson & Johnson (JNJ) ($70.34 vs $68.29 on Aug 8) still has a buy rating according to ValuEngine and is above its 200-day SMA at $66.53. My quarterly value level is $68.76 with an annual pivot at $70.65 with my annual risky level at $75.79.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
